Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea Tel: +82-31-787-8133, E-mail: [email protected] Copyright 2025 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Users in their forties, fifties, and beyond frequently describe feeling like they did a decade or more earlier
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
Did Phase 1 trials show any serious safety concerns
By indication, type-2 diabetes remains the largest segment (57.6% of 2024 GLP-1 revenue, ~$31.1B) ( [22] ), followed by cardiovascular risk reduction (~19.6%, $16.0B) and obesity (~12.8%, $6.9B)
Currently, Bellwether trials are expected to begin in late 2026 or early 2027, but these dates may change
Pharmaceutical companies have invested heavily in improving injection devices to enhance patient convenience and adherence
